TSS
DMAC icon

Two Sigma Securities’s DiaMedica Therapeutics DMAC Stock Holding History

Two Sigma Securities’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,511
Closed -$136K – 1638
2021
Q2 		$136K Buy
+30,511
New +$250K ﹤0.01% 1328

Other funds holding DMAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Securities's DMAC Position: Q3 2021 in Review

Two Sigma Securities sold out of DiaMedica Therapeutics (DMAC) in Q3 2021, closing a stake of 30,511 shares — an estimated $136K sold.

Two Sigma Securities first reported a position in DMAC in Q2 2021 and held it in 1 quarter. The position peaked at $136K in Q2 2021. 34 funds tracked by Wall St. Rank hold DMAC as of Q3 2021.

  • Two Sigma Securities reported no remaining DiaMedica Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Securities sold 30,511 DiaMedica Therapeutics shares in Q3 2021, an estimated $136K.
  • Two Sigma Securities first reported a position in DiaMedica Therapeutics in Q2 2021 and held it in 1 quarter.
  • Two Sigma Securities's DiaMedica Therapeutics position peaked at $136K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2021.

Based on Two Sigma Securities's 13F filing for Q3 2021, filed 15 Nov 2021.